Pemphigus

Patients with pemphigus in complete remission had a reduced risk of relapse after receiving an additional rituximab infusion at month 6, according to a study.

In patients with pemphigus vulgaris and pemphigus foliaceus, adjuvant immunoadsorption did not lessen the time to clinical remission, according to a study.

The Skindex-16, a clinical tool for measuring the skin-related quality of life of patients, showed that patients with autoimmune bullous diseases are greatly impacted by disease flares, according to a study.

Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but similar in survival rate, compared with other adjuvant agents in the treatment of pemphigus, according to a study.

Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been treated with rituximab, according to data published in JAMA Dermatology.

Superficial radiotherapy yielded complete remission in 90% of treated areas in a small cohort of individuals with Hailey-Hailey disease, according to recent findings.

Bruton tyrosine kinase inhibitor rilzabrutinib, in association with longer treatment, showed improved clinical activity in patients with pemphigus, according to a study reported at the American Academy of Dermatology virtual meeting.

Initial score on the Pemphigus Disease Area Index and evolution of anti-desmoglein antibody values 3 months after an initial cycle of rituximab are associated with short-term pemphigus relapse, according to a post hoc analysis of a randomized clinical trial published in JAMA Dermatology.